Miguel MГјller Frank
So konzentriert sich Michael Strmer in Die Reichsgrndung auf Bismarck und die Jahre  hnlich wie Strmer stellt Frank Lorenz Mller die Frage, ohne sie eindeutig zu Krause, Gerhard and MГјller, Gerhard (eds), Berlin / New York: Walter de. MГјller-Gorchs -MACROS-, SektorenГјber- greifendes mich zu unterstГјtzen вЂў Ebenso Ingo und Frank fГјr ihre wichtigen Hinweise вЂў Simone und Miguel Delgado is a month-old lad who is admitted to the pediatric section for the. Rasarus, Rasul, Samuel and Miguel Papua new guinea Alleinreisende als HГ¤tschelkinder der Touristik -MACROS-, Frank- furter Allgemeine Zeitung vorge- stellte stammesgeschichtliche GroГџablauf der Wirbeltiere nach MГјller Category: filme stream kinox Rasarus, Rasul, Samuel and Miguel Papua new guinea Alleinreisende als HГ¤tschelkinder der Touristik -MACROS-, Frank- furter Allgemeine Zeitung vorge- stellte stammesgeschichtliche GroГџablauf der Wirbeltiere nach MГјller
Miguel MГјller Frank Contribute to This Page VideoDie Araberherde vom Haupt-und Landgestüt Marbach Resides in Nashville, TN. Includes Address 10 Phone 7 Email 1. No sooner do the other Amazons find out, a cat fight ensues, and One Eye Jack's band of pirates pop up again. Lived In Atlantic City NJ, Online Casions Point NJ, Ocean View NJ, Woodbine NJ.
Cronje, M. Vrba, P. Lady Isis Rose. Vincent Tremayne. Flounder Publications. House of Commons. Liaison Committee.
Michael R. Hua Lang. William Lambers. Robert Leach. Carolyn Keene. Robert Allen Meyers. Philip R. Ray Reutzel, Robert B. William R. Newman, Lawrence M.
Sharon Kay Riddle. Lawrence Paul, George Harris, Annette Schroeter. United States Government Printing Office.
Thomas F. Goldman, Henry R. Property Services Agency Staff. Karl Popper. Geoffrey Boothroyd. Heather Chick.
Botswana, Sept. Corey Sandler, Janice Keefe. Sandra Labruce. Anne Barab, Tracy Brown, Bob Karstens, Karl J. Krayer, J. Maroney, Harriet Meyerson, Idell Moffett, Gary Rifkin, Mark J.
Sadlek, Ellen Spencer, Kelli S. Vrla, Rhonda Wildman. Amjad Umar. Bijan Jabbari. Jean Racine. Arthur Stanley Maxwell.
David Carson. Margie Gray, Laura Ingalls Wilder. Chris Etheridge. Cherryl Moote. Roy M. Don A. Stephen F. James Peter Stanton. Patti Spinelli.
Jerry B. Day, Gunnison County Pioneer and Historical Society. Paul Thompson, David Lane. Joy Perrine. Conrad Bishop, Elizabeth Fuller. Paul Jurmo, Sue Folinsbee, ABC Canada.
Don Ward. Francoise Wilhelmi de Toledo, Hubert Hohler. Jeff Savage. John Updike. Alexander Agricola. Adam Gamble. Ibanga 1.
Meir H. Jacques Werth, Nicholas E. Donna Leon. Beginner Believers Ministries, Incorporated. Dennis F. Prentice Hall PTR.
Neff, Scott H. Rose, Museum of Science and Industry Chicago, Ill. FCO Services, Great Britain. Tom McLachlan, Kate Skye. James D. Halderman, Jim Linder.
Catherine M. Stationery Office Staff. HSP, Harcourt School Publishers. Ernest J. Edgar Ewing, Max F.
Schulz, Fisher Gallery University of Southern California. Colin Barrow. Paul Jensen. Sunbird Readers. Bruce W.
David Krogh. Margaret Wise Brown. Peter Demetz. Aristides George Paradissis. Claudia Panuthos, Catherine Romeo. John Winters, Maxine Barish-wreden, M.
Storrs Charles H. Logan Associate Professor of Sociology University of Connecticut. Peter Honey, Alan Mumford.
Larry Marion. Peter A. McWilliams, Michael O'Rourke. Great Britain: Advisory, Conciliation and Arbitration Service. John Santrock. National Aboriginal and Torres Strait Islander Program.
Norman Crosby Getchell. Matthew Cornick. National Radiological Protection Board, Great Britain. National Audit Office. Marisabina Russo.
Que Lustrationes. Kieran O'Mahony, Rodney Broome. Carol A. Mik Schellback. Ed Wagner. Wallace Stegner. Nicolaus Associates. Annie Wilder.
Sven Nordqvist. William Somerset Maugham. Japan Publicity, Incorporated. Michael Leslie, Nicholas G. Myra Goldberg.
Max Weber. Teacher Guide,. Alice Barlow-Kedves. Roderick Hunt, David Hunt. Clare Moore, James Edward Moore. Penelope Williams. Gene E.
Pesticides Safety Directorate Staff. Richard Rice. Julie Tallard Johnson, Kristine Merrill, Jere Truer. Lloyd J.
Dan Felder. Kevin Wolfe. William L. There Is an Answer. Orchid Publishing Company. Patricia Irons. Martha S. Martin, Thomas H.
Martin, Mark Charles Werthman. Committee on Foreign Relations. Tami S. Karen Irvine, Patrick Thomas. Jill Franklin. Mohammad Hashim Kamali. Holly Devor.
Del Hunter Morrill. David Snashall, Dipti Patel. Alice Bertha Gomme. Gerry Mullins. NET 4. Jason N. Gaylord, Christian Wenz, Pranav Rastogi, Todd Miranda, Scott Hanselman.
Harcourt Brace, Richard G. Elizabeth W. Jeneanne Sieck. Ian Fleming. Sandy Baker. Ananda Breed. Hubert Campfens.
Joe Upton. Richard C. Michael Coleman. Rosemary Ashton. Richard E. Prior, Joseph Wohlberg. Aleksey D. Neil A. Campbell, Brad Williamson, Robin Heyden.
Kenneth H. Steven Carroll. Peter Cooper. Ridgeway, Gillian, Kathryn Harvey. Jane Kempf. Morter, Jr.. Monica Carter. Beulah Joy McGuinness.
Victoria S. January 22, January 28, February 23, January 20, January 29, Committee on the Budget. Herbert C. Globe Fearon.
Roman Statnikov, Alexander Statnikov. Sheena Grant. Committee on Education and Labor. Subcommittee on Postsecondary Education.
Gillian Stead. Jayc G. Robert Forrest Williams. Larry T. Shepherd, Thomas J. Frederick Clarkson. PAM JOHNSON-BENNETT.
Jacky Davis. Howard Koch, Julius J. Barbara Rose. Bobby Rexrode. Pauline Correia Stonehill. Arthur Goldschmidt, Lawrence Davidson.
Ian P. Howard, Brian J. Valery M. Lewis S. Association of Science-Technology Centers. Eric Hayot. Corbel, Ghislaine, Association des auteurs de l'Ontario.
John Hollander. Pete Mitchell. Tony Zigmond. Adrienne Kollenberg. Sergio Troncoso. Edward A. Ted Smith. Ken Coffman. Leo Braudy. Stewart Jay Brown.
Bruce E. Monica Hughes, Jan Burchett, Sara Vogler, Alison Hawes, Paeony Lewis, Nikki Gamble, Thelma Page. Betty Gilderdale. Jeffrey L.
Douglas W. Woods, Jonathan Kanter. Rex Bernardo. Prentice- Hall, inc. Reader's Digest Association. Allen J.
Wood, Bruce F. Michael Ashley. Erika Goulden, Linda Goulden. Committee on Government Reform and Oversight. Subcommittee on Human Resources.
Christopher McIntosh. Yasunari Kawabata. Walker Percy. Tarek Mohamed Hassan, Jilin Ye. Rex Ever Found. Steve Fiffer. Harvey Newcomb.
Music edition. Kelly Leiter, Julian Harriss, Stanley Johnson. Maurine A. Fry, Jerry D. Harris, Margaret Early. Tom Loizos.
Linda Lazarides. Mihailo Crnobrnja. Kelsang Gyatso. Robert Redfern. John Stevens. Nancy Callan. Geoffrey Goodwin. The law cannot contain and voice our strivings for the communities we want to have and our aspirations for the people we want to be.
Nevertheless, Christodoulidis continues to see a vital role for the constitution. This is most markedly obvious as republican constitutional scholars attempt to make constitutionalism reflexive and inclusive.
According to him, this demand on constitutionalism is an impossible one because it attempts to make an inherently institutional concept constitutionalism open to radical transformation.
Consequently, Christodoulidis develops a theory of politics that emanates from a constituent power. Christodoulidis stabilizes his notion of a constituent power via an underdetermined communal subject that is formed through praxis, that is, a subject that is always in a process of always becoming.
Consequently, the political task at hand is maintaining the possibility for reflexivity, dissent, and disagreement over these boundaries.
While Christodoulidis emphasizes the need to draw attention to the limits of these boundaries, he does so by way of maintaining the role of constitutionalism in the production of community.
While he acknowledges the danger of asserting a conception of an immanent community, he nonetheless produces one that is recognizable by its praxis.
This community is not nothing; it is something. The equation of the political with the sovereign will of a community of human actors forgoes a consideration of the plurality of the world.
Writing the Interruption of Community Community cannot be thought of through rights, social contracts, or romantic notions of the people.
There is that there is. This is because the representation of the world requires a subject to be outside of the world and this is an impossibility.
Justice is in the constant movement of this sharing, irreducible to an end, model, or product. And it is this sharing of the world that must be articulated, interrupting the myths of community that deny this being-in-common.
In order to do justice to the truth of being-in-common, museum practices and constitutionalism must articulate the sharing and exposure of the world.
Such an endeavor entails a retreatment of the political that refuses to set the production of community as its task.
This means that both museum practices and constitutionalism must refuse sovereignty, but not by taking refuge in this denial. Such refuge would only establish a new self-assured conception of the political with a new mythological veneer and coherence.
Rather, a retreatment of the political at the museum and in constitutionalism means an incessant articulation of the infinite sharing of community.
It means the constant writing of the exposure of existence, an exposure that interrupts the logic of communion.
Future museological projects are proposed as interactive installations aimed at developing critical museum visitors, and others as theoretical gestures intended to reconceptualize relations between the museum and its visitors.
This privation of community makes a project or work out of community. The aim of reforming the museum is therefore not merely a well-intended project of restoring what is missing although its promoters may think of it that way ; rather, these projects serve as active authorizers of the concepts and categories used to demarcate and delimit community.
Despite its origins in antifeudal movements, however, the modern public museum maintained many of the traps of the hierarchical systems that the revolutionaries were purportedly trying to expel.
This transposal is most obvious in the fact that new public museums became a site from which state agendas of governance and nation building were launched.
The public museum was a site for instantiating a newly emerging public, positioned as the owners and keepers of national collections but also subject to its disciplinary demands.
These modern themes of collective ownership and universal representation set the parameters for the museum to become a site of controversy and contestation over democratic ideals, representation, and reform in the nineteenth and especially the twentieth century.
Indeed, the modern state is asserted to have emerged out of this same rejection of the monarchical tradition; the popular will of the people is now presumed to have taken its rightful place at the autonomous helm of the secular, liberaldemocratic state.
In both stories, the oppressive force of unelected rulers is imagined to be a distinct thing of the past.
But this new landscape offers a suffocated notion of the political for both museums and constitutions, one that asks us to set our horizons on the power of sovereignty.
The formation of the modern public museum is intimately bound up with the social, political, and historical emergence of liberalism.
Carol Duncan outrightly characterizes museums as sites of secular ceremonies. A critique of both the museum and the constitution as merely institutions dedicated to civic rituals, while true, does not go far enough.
In doing so, however, these attempts continue to centralize existing categories of community and consistently equate democracy with inclusion and better representation at the museum.
In my view, such limited calls for reform cannot do justice to the ontological primacy of being-in-common nor can they proffer responses to legacies of colonialism.
Attending to these complex legacies of exclusion and marginalization requires an unthinking of the hegemony of this atomized subject and its representation, which continues to hinge on imaginations of autonomy and sovereignty inherited from Western systems of law and politics that were institutionalized in museums and constitutions in the seventeenth and eighteenth centuries.
Two of the most famed naturalists of the time, Conrad Gesner Swiss and Ulisse Aldrovandi Italian , wrote encyclopedias and articles that conveyed a plethora of categories describing the objects they had collected.
One such influence was an increasing need to legitimize the role of the prince and the monarchical dynasty as a result of the destabilizing effects of the Protestant Reformation in Western Europe at the time.
The advent of the contemporary public museum descended from the revolutionary traditions of Western Europe. Its place as a public institution came largely as a result of antifeudal demands that transformed political and cultural society, especially the private ownership of royal collections.
The collections were to be of service to the citizenry, displaying objects and artifacts for the masses. Rather, the new democratic institution envisioned by the revolutionaries simply substituted the centrality of the monarch with the centrality of the state; there was no radical transformation in the physical or symbolic organization of the objects.
This shift paved the way for the introduction of modern scientific taxonomy. In The Order of Things, Foucault notes that until the middle of the seventeenth century, history was the inextricable and completely unitary fabric of all that was visible of things and of the signs that had been discovered or lodged in them: to write the history of a plant or an animal was as much a matter of describing its elements or organs as of describing the resemblances that could be found in it, the virtues that it was thought to possess, the legends and stories with which it had been involved, its place in heraldry, the medicaments that were concocted from its substance, the foods it provided, what the ancients recorded of it, and what travellers might have said of it.
The history of a living being was that being itself, within the whole semantic network that connected it to the world. The method was predicated on a newly emerging epistemological thrust that sought to uncover hidden relations in and between beings, a method notably different from sixteenth- and early seventeenth-century conceptions of historical technique.
In so doing, the object of study became knowable as and through these categories. Finally, the difference between the Classical and the Modern episteme is best characterized as one that shifts the importance from taxonomic representations of the object i.
Foucault claims that the emergence of biological science in the Modern period brought along with it the notion of evolutionary thought and genealogical connection, a move that also meant a retreat of the emphasis on visible representations in the sciences.
Foucault argues that the shift from the Classical to the Modern period brought along an attendant shift from sovereign, to disciplinary, and then biopolitical power, the latter a power concerned with the management of life and populations rather than individual bodies through techniques of normalization such as programs of monitoring and normalizing hygiene, as well as reproduction, birth, and mortality rates.
Specifically, the evolutionary narratives found their way into museum exhibition practices not only in the arrangement of objects animated by an evolutionary connection, but also in the framing of man as on a historical evolutionary path moving toward eventual flawlessness.
In their new conceptions, museums exhibited objects in relation to a scientific rationality that conferred new symbolic meanings on the objects and, importantly, the relationship between objects.
This was purported to occur by having the working class attend the museum, where they would see their esteemed compatriots acting with good manners and, subsequently, would emulate the appropriate behavior.
This educational project aimed at the working class had a double function of managing behaviors and interpellating them into an imagined community of national subjects.
Through the new evolutionary thrust of the museum, these subjects were imagined as a public organized by a unique time and place that distinguished them as a citizenry situated at the culmination of the evolutionary processes laid before them.
Contemporarily, the museum extends a forceful narrative of universal education using the rhetoric of multiculturalism. It claims to universally represent while, at the same time, it actively differentiates between populations both in how it grants or does not access to collections and through the representations it provides.
This was not the case with the collections and studiolos of princes and naturalists who made no such claim to universality. Most importantly, these calls for reform and for better representation are structurally insatiable; the museum will never be able to satisfy them.
It also occurs in the very foundational technologies of the museum. To illustrate, Donald Preziosi compares the epistemological practices of the museum to a grammar textbook that he had as an elementary school student.
The cover of the grammar book, he explains, was a picture of a room littered with prepositions in order to literally illustrate their spatial-temporal meanings.
These technologies allow for the emergence of the knowable, locatable, and explainable notion of the individual in modernity.
Museum visitors do not experience the potential loss of self; rather, through the unfolding of magical chronological time, they experience its putting-in-place, or legibility.
Reforming the Museum The violence of these museological techniques is certainly not news to most. Indigenous individuals and communities, as well as postcolonial scholars and activists, have criticized the orientalizing effects of large public museums in Europe and the former colonies.
I argue that these proposals confuse their project of representation with democracy. In her book Making Representations: Museums in the Post-colonial Era, Moira Simpson explores various histories of exhibitions from the United Kingdom to Canada and the subsequent calls for more adequate representation articulated by activist groups, individuals, and communities.
She charts the legal, political, and social routes that people have taken to make demands on the museum to recognize institutionalized practices of orientalism, exclusion, and the perpetuation of colonial legacies through exhibitions.
Her goal is to develop a museology that contributes to the cultural and economic development of indigenous communities.
It is her hope that, if made successfully, such claims will assist in the legitimation of indigenous rights and, subsequently, the increased political, social, and economic standing for those individuals and communities.
New museum theory is about decolonizing, giving those represented control of their own cultural heritage.
This assertion runs up against at least four fundamental problems. First, depictions of individuals and communities through museological practices are necessarily limited and will, therefore, always be fundamentally unable to answer entirely to these claims.
Any museological display that claims to represent a reality outside of its walls can always be accused of formulating an incomplete picture.
Having a place as a citizen in the modern state also means being subject to its biopolitical management. This is a particularly critical concern for indigenous groups in the North American context who want to contest state-endorsed conceptions of community, history, and politics.
Denial of this impossibility allows us to tell mythological stories about sovereign selves and sovereign communities, which fail to attend to the truth of our existence.
Lastly, as these projects import the myth of sovereignty, they recenter the modern Western concern with atomization, both individual and collective.
It is this persistence of the absolute, of sovereignty, however, that acts as a barrier to anticolonial thinking.
Museum scholar Amy Lonetree would likely take issue with my position. Our survival, as many people have argued, is one of the greatest untold stories, and the specifics of this difficult and shameful history need to be told.
Mark Rifkin explores the powerful prospect of using indigenous poetry and fiction to write conceptions of sovereignty that resist the racial logics and colonial categories proffered by the United States settler state government.
He refuses a distinction between what might be considered abstract writing and formal politics. This does not mean, however, that there is no place for museums.
While, taking inspiration from Lonetree, we might not want to abandon representationally reparative projects in their entirety, I want to surface important concerns about what is at stake in investing in promises of restoring community in the name of democracy.
This concept is intended to extend beyond internally proposed reforms, which its proponents argue retain dominant social relations fostered at the museum.
Thick democracy promotes the value of dialogue in the production and execution of a museum exhibit. Indeed, in her attempt to open up the historically narrow conceptions of the citizen, she draws on a conception of the international institution that is popularly believed to be a sacred protector of extra-state human rights.
Like her state-based concept of democracy, however, the justice sought through international conventions set by the United Nations continues to turn on a logic that centers the same conception of sovereign individuals and social contracts.
While Golding seeks to challenge the limited politics of Western state-based democracy, her attendant exaltation of the United Nations convention fails to identify the consistent underlying logic in both.
James Clifford also attempts to draw out a more inclusive theory of museum exhibition development. But his conception of copresence retains at its foundation separate and distinct subjects who find their copresence through their interactions.
His theory hinges on a concept of individuated subjects that happen upon their copresence through acts of volition, rather than as a result of the ontological sharing of their existence.
Another strategy of attempting to address the hierarchical and exclusionary practices of the museum is a move toward more interactive museum exhibits through concentrated physical and mental stimulation.
This might involve a quiz or set of questions in which the participant hazards a guess and then is told if the answers are right or wrong.
While this may be an observable trend, this framework of critique does not get to the heart of the matter. Rather than dispensing with the guiding force of these destinal figures, interactive programming reinvigorates it, promising a chance at ultimate communion through a more immersive experience.
These reforms reinforce a conception of democracy that is predicated on better representation, rather than destabilizing the concept of community at its core.
As my genealogy of the modern museum indicates, this investment in sovereignty is as likely to appear in postwar and revolutionary museums as it is in exhibits borne out of neoliberal societies.
This is not a rejection of a historical analysis but a demand for a longer view that is able to perceive the influence of liberalism on our collective imaginations, which goes beyond the last forty years of Hayekianinspired economic thinking.
Interrupting Anamorphic Orientations A rethinking of the political means a rejection of the equation between the foundation of community in institutional representations and the political.
This is essential to the untying of the k nots of community and a thinking of the k not as still to be tied: It is in all respects not only reasonable, but also required by the vigor and rigor of thought, to avoid recourse to representations: the future is precisely what exceeds representation.
And we have learned that we must grasp the world once more outside of representation. A concept of the political that does justice to being-in-common is a writing of ontological sharing.
It is against the destinal figure of community. It is against the anamorphic orientations that classify, order, and cohere relations between objects and museum visitors.
It is against the ascription of essence to objects, visitors, and history that denies their existence as exposure.
Preziosi explains that, in modernity, not knowing what you are looking at in a museum is tantamount to not knowing when you are. He claims that the subject who gazes on the object occupies a place simultaneously inside and outside of history.
They are at once the product of history, at the end of history, and, significantly, linked to the future. We speak as fellow citizens to heal the wounds of the past with the intent of constructing a new order based on justice for all.
It is a naturalized notion of continuous time that provides the backdrop for these prophesied transformations. As such, conceptions of time become central in orienting the relationship between an imagined past and an imagined future by telling a narrative from which political projects, communities, and subjects are imagined, rendering the messiness of political community into an ordered whole.
In this way, time functions as an anamorphic orientation at work in the museum. The notion of continuous time emerges, at least in part, from the transformation of a theological organization of the world to the rise of the modern state.
During this period, interpretations of time shifted from fixed and finite to enduring and infinite.
These institutions have continued to gather their legitimacy from this conferral of continuous time while denying their theological inheritance.
The coterminous rise of time as infinite and the development of the modern state have resulted in a deep attachment to the notion of enduring time for contemporary conceptions of political community.
Carl Schmitt asserts that these theological underpinnings of the modern liberal state must be revealed. He critiques the mythical sense of permanence that is conferred on the modern state and its conflation with sovereignty.
But where Schmitt responds to the paradox of the supposedly secular modern state by galvanizing the sovereign remnant at its core, Benjamin wants to deactivate, or depose [Entsetzung] it.
Benjamin finds his alternative in the notion of messianic time, a temporality that demonstrates how interruptions and cessations in the naturalized flow of chronological time can depose sovereign authority.
In this chapter, I elucidate how the notion of continuous time is used to orient and authorize the categories of politics, community, and the subject at the museum.
This gentle shaping of the horizons of intelligibility informs what kinds of politics, communities, and subjects are authorized as thinkable.
For example, senior staff members at the British Museum equate their conception of democracy with the inclusion and cohesion of diverse communities and the attendant achievement of a redemptive future.
Through such narratives, the contemporary museum visitor is imagined as situated at the end and as the culmination of a progressive teleology.
This notion of time as progress is not only articulated by the staff, but also by students participating in museum programs.
These anamorphic orientations are also contested, however. Thus, although time as an anamorphic orientation helps lend an authoritative gloss to the political projects at the museum, it is not totalizing.
Rather, while linear, continuous time functions to cohere political community at the museum, it is also interrupted and made inoperative by the interminable messiness of the world.
While these sporadic interruptions may be the kind of messianic events that Benjamin is inclined toward, such disruptions do not only have to be left to entirely unpredictable occasions.
The significance of these events can also be embraced by the everyday practices of the museum. In other words, the museum does not only have to function as a manager of the world and its populations, it can also participate in its disruption and provide an interruption to the logic of communion.
At the end of this chapter I intimate that while museums can interrupt this logic, they must, not only in a haphazard way through confusion and misunderstanding, but through a continuous writing of the essenceless of community.
Before the thirteenth century, time was largely thought of as something that was created by God and that could be taken away at any given moment.
Thus, the imminent arrival of the end of the world, as propagated by the Christian teachings and given authoritative weight by the Holy Roman Empire, maintained a conception of worldly time as fixed.
While the afterlife might provide immortality for individuals in heaven, the perpetually looming end of the world meant the end of worldly time.
Eventually these so-called para-ecclesiastical institutions left the Church itself behind. Schmitt criticizes champions of liberalism for denying and disguising the role of decisionism that lies at the heart of parliamentary democracy.
Where liberal democratic constitutionalists, like Hans Kelsen, think they can predict all legal situations with a set of positive laws, Schmitt argues there will inevitably be situations that exceed the boundaries of constitutions, charters, and bills of rights and will require a decision made by an human actor.
He is not concerned with eradicating this truth, but with naming it and treating it for what it is. Therefore, while he claims that the piercing time of the exception can break through the torpid time of liberalism, he ultimately follows what he sees as the undeniable power of sovereignty.
For Benjamin, sovereignty is not inescapable; there is a way to resist it or depose of it. Whether the dominant group is in the position of power or those roles are reversed, both groups seek to secure their place at the helm, thereby maintaining the structure of power that legitimizes violence.
They have in mind a telos, a form, or a goal; they have intention. In the proletarian strike, workers stop the functioning of state apparatuses by refusing to work.
They have no additional political agenda or preconceived goal. Rather, in withdrawing their labor their actions thwart state power as well as the logic of intention and utility that undergirds it.
The former, for him, is the product of the utilitarian-driven, power-asserting force of law. Constitutional law is a prime example as it legitimizes the power and authority of the victors in the very foundation of the social contract.
This authorization grants the power-holders the ability to distribute rights to those it has vanquished through law-establishing violence.
Time as progress is a tool that lends itself to the authorization of law-founding and law-preserving violence. Benjamin likens this scene to the depravity of the contemporary obsession and naturalization of progress.
The angel is looking at the past but where we see history, the angel sees nothing but tragedy after tragedy, compiled into one giant catastrophe. And although the angel would like to stay to make things better, an unstoppable wind is blowing him backwards into the future.
This storm is what we call progress. In contrast to the sovereign fetish of mythical violence, divine violence cannot be willed or brought forth by intentional human agency.
It is not concerned with achieving sovereignty but with deposing it. Like the proletarian strike, it does not invent a new order or program but merely offers a fleeting moment of interruption: Where mythic violence is law-establishing, divine violence destroys law; where the first sets bounds, the second wreaks boundless destruction; where mythic violence apportions blame and calls for expiation simultaneously, divine violence expiates; where the former threatens, the latter strikes; where one is bloody, the other, albeit lethal, kills without blood.
He rejects the fetish of manmade sovereignty that perpetuates violence in the name of utilitarianism.
But what then does this mean for the practices of constitution writing and museum exhibiting and their critics?
One way to do this is through the method of montage. Thus this project is largely oriented around adult literacy for individuals whose first language is not English.
The political project imagined by the staff at the British Museum is intimately tied to a teleological conception of time that has its end in a redemptive future.
As one staff member notes, one of the aims of the programming is to get participants to return to the museum with their friends and family: We do also value the need to diversify our audience and to create a diversity within our audiences.
Contained within this goal is an unspoken assumption about the virtuosity of universal representation used to augment the communing logic at work.
The notion of time as continuous and redemptive also carries with it a transnational hope for a future universal humanism.
For at least one staff member, the political project being carried out at the museum is one of making people understand that all humans are similar.
Fiegl M, Stauder R, Steurer M, Mian M, Hopfinger G, Brychtova Y, Skrabs C, Zabernigg A, Schmid F, Haslbaur F, Winder G, Walder A, Lang A, Voskova D, Greil R, Mayer J, Gastl G Ann Hematol.
Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC and UCHL1.
Mod Pathol. Epub Dec 6. Tecemotide L-BLP25 versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer START : a randomised, double-blind phase 3 trial.
Epub Dec 9. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Knauer M, Singer C, Jakesz R, Dubsky P, Fitzal F, Bartsch R, Steger G, Balic M, Ressler S, Cowens JW, Storhoff J, Ferree S, Schaper C, Liu S, et al.
Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.
Taylor N, Haschke-Becher E, Greil R, Strasser M, Oberkofler H. Antivir Ther. Epub Jan Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.
Guglielmelli P, Biamonte F, Rotunno G, Artusi V, Artuso L, Bernardis I, Tenedini E, Pieri L, Paoli C, Mannarelli C, Fjerza R, Rumi E, Stalbovskaya V, Squires M, Cazzola M, Manfredini R, Harrison C, Tagliafico E, Vannucchi AM Blood.
The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.
Clin Cancer Res. Epub Feb Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival.
Pleyer L, Germing U, Sperr WR, Linkesch W, Burgstaller S, Stauder R, Girschikofsky M, Schreder M, Pfeilstocker M, Lang A, Sliwa T, Geissler D, Schlick K, Placher-Sorko G, Theiler G, Thaler J, Mitrovic M, Neureiter D, Valent P, Greil R.
Effect of radiotherapy after mastectomy and axillary surgery on year recurrence and year breast cancer mortality: meta-analysis of individual patient data for women in 22 randomised trials.
EBCTCG Early Breast Cancer Trialists' Collaborative Group , McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S.
Epub Mar Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients.
Epub May 5. Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives. Hohla F, Winder T, Greil R, Rick FG, Block NL, Schally AV.
World J Gastroenterol. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, et al.
N Engl J Med. Epub May Oxaliplatin, fluorouracil and leucovorin with or without cetuximab in patients with resected stage III colon cancer PETACC-8 : an open-label randomised phase 3 trial.
Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C Lancet Oncol.
Epub Jun Azacitidine in patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group.
Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays, an ERIC-wide approach. Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II IIIA and IIIB TAX-AT 1.
Kocher F, Pircher A, Mohn-Staudner A, Romeder F, Duller W, Steinmaurer M, Eckmayr J, Schmid T, Hilbe W, Fiegl M, Greil R.
Lung Cancer. Epub Jul 3. A patient diagnosed with BRAF-mutated non-small cell lung cancer and hairy cell leukemia: at last, which entity is really carrying the BRAF mutation?
Schlick K, Troch M, Placher-Sorko G, Faber V, Neureiter D, Berghoff AS, Preusser M, Greil R, Hopfinger G.
Epub Jul MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis.
Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC Br J Haematol. Epub Aug 8. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, et al.
Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses.
Brodowicz T, Lang I, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Petruzelka L, Eniu A, Anghel R, Koynov K, Vrbanec D, Pienkowski T, Melichar B, Spanik S, Ahlers S, Messinger D, Inbar MJ, Zielinski C.
Preoperative Treatment with Capecitabine, Cetuximab and Radiotherapy for Primary Locally Advanced Rectal Cancer - A Phase II Clinical Trial.
Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients. Blank PR, Filipits M, Dubsky P, Gutzwiller F, Lux MP, Brase JC, Weber KE, Rudas M, Greil R, Loibl S, Szucs TD, Kronenwett R, Schwenkglenks M, Gnant M.
Dittrich C, Fridrik MA, Koenigsberg R, Lee C, Goeldner R, Hilbert J, Greil R. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma GHSG HD13 : an open-label, randomised, non-inferiority trial.
Pleural decortication of a marginal zone lymphoma. Melchardt T, Weiss L, Namberger K, Pretsch I, Hutter J, Rettenbacher L, Neureiter D, Troch M, Greil R, Egle A.
Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. Weiss L, Melchardt T, Habringer S, Boekstegers A, Hufnagl C, Neureiter D, Hopfinger G, Greil R, Egle A.
Epub Dec 3. Human immunodeficiency virus type 2 infections in Austria. Taylor N, Kern JM, Prammer W, Lang A, Haas B, Gisinger M, Zangerle R, Egle A, Greil R, Oberkofler H, Eberle J.
Liver toxicity during temozolomide chemotherapy caused by Chinese herbs. Melchardt T, Magnes T, Weiss L, Grundbichler M, Strasser M, Hufnagl C, Moik M, Greil R, Egle A.
BMC Complement Altern Med. Melchardt T, Weiss L, Hufnagl C, Neureiter D, Kemmerling R, Morre P, Boekstegers A, Hopfinger G, Auberger J, Steinkirchner S, Pleyer L, Greil R, Egle A.
C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients.
Troppan KT, Schlick K, Deutsch A, Melchardt T, Egle A, Stojakovic T, Beham-Schmid C, Weiss L, Neureiter D, Wenzl K, Greil R, Neumeister P, Pichler M.
Kasabach-Merritt phenomenon in hepatic angiosarcoma. Habringer S, Boekstegers A, Weiss L, Hopfinger G, Meissnitzer T, Melchardt T, Egle A, Greil R.
Them NC, Bagienski K, Berg T, Gisslinger B, Schalling M, Chen D, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Zagrijtschuk O, Klade C, Greil R, Gisslinger H, Kralovics R.
Epub Mar 2. The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study ABCSG Steger GG, Greil R, Lang A, Rudas M, Fitzal F, Mlineritsch B, Hartmann BL, Bartsch R, Melbinger E, Hubalek M, Stoeger H, Dubsky P, Ressler S, Petzer AL, Singer CF, Muss C, Jakesz R, Gampenrieder SP, Zielinski CC, Fesl C, Gnant M Ann Oncol.
Hofbauer SW, Krenn PW, Ganghammer S, Asslaber D, Pichler U, Oberascher K, Henschler R, Wallner M, Kerschbaum H, Greil R, Hartmann TN.
Epub Feb 5. Hutterer E, Asslaber D, Caldana C, Krenn PW, Zucchetto A, Gattei V, Greil R, Hartmann TN. Epub Oct Gnant, M, Mlineritsch, B, Stoeger, H, Luschin-Ebengreuth, G, Knauer, M, Moik, M, Jakesz, R, Seifert, M, Taucher, S, Bjelic-Radisic, V, Balic, M, Eidtmann, H, Eiermann, W, Steger, G, Kwasny, W, Dubsky, P, Selim, U, Fitzal, F, Hochreiner, G, Wette, V, Sevelda, P, Ploner, F, Bartsch, R, Fesl, C, Greil, R Ann Oncol.
Hinterseer E, Stiefel O, Neureiter D, Kandler G, Vogt S, Hutter J, Strasser G, Greil R, Hartmann TN, Hopfinger G. Targeting proliferation of chronic lymphocytic leukemia CLL cells through KCa3.
Alternative splice variants of AID are not stoichiometrically present at the protein level in chronic lymphocytic leukemia.
Rebhandl S, Huemer M, Zaborsky N, Gassner FJ, Catakovic K, Felder TK, Greil R, Geisberger R. Epub Apr APOBEC3 signature mutations in chronic lymphocytic leukemia.
Huemer M, Rebhandl S, Zaborsky N, Gassner FJ, Hainzl S, Weiss L, Hebenstreit D, Greil R, Geisberger R. Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia.
Gassner FJ, Zaborsky N, Neureiter D, Huemer M, Melchardt T, Egle A, Rebhandl S, Catakovic K, Hartmann TN, Greil R, Geisberger R. Protein Kinase C-?
B in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B Cells In Vivo. Cancer Cell.
Valente LJ, Gray DH, Michalak EM, Pinon-Hofbauer J, Egle A, Scott CL, Janic A, Strasser A. Cell Rep. Epub May 9.
Bid-ding for mercy: twisted killer in action. Egle A, Asslaber D, Villunger A, Pinon-Hofbauer J. Cell Death and Differentiation.
Melchardt, T, Weiss, L, Egle, A, Dtsch Med Wochenschr. Epub Oct 1. CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism.
Zucchetto A, Caldana C, Benedetti D, Tissino E, Rossi FM, Hutterer E, Pozzo F, Bomben R, Dal Bo M, D'Arena G, Zaja F, Pozzato G, Di Raimondo F, Hartmann TN, Rossi D, Gaidano G, Del Poeta G, Gattei V.
Updated report of the Austrian CML registry Schmidt, S, Burgstaller, S, Linkesch, W, Greil, R, Schlogl, E, Fridrik, M, Krieger, O, Petzer, A, Lang, A, Mitterer, M, Valent, P, Walder, A, Sliwa, T, Keil, F, Korger, M, Hausler, C, Woll, E, Oexle, H, Schnallinger, M, Pober, M, Rochau, U, Siebert, U, Thaler, J, Gastl, G ONKOLOGIE.
Lapatinib plus Caelyx in patients with advanced or metastatic Her 2 positive breast cancer following failure of Trastuzumab therapy - A Phase II study of the Arbeitsgemeinschaft Medikamentose Tumortherapie Pircher, M, Mlineritsch, B, Fridrik, M, Dittrich, C, Lang, A, Petru, E, Weltermann, A, Thaler, J, Hufnagl, C, Gampenrieder, SP, Ressler, S, Rinnerthaler, G, Ulmer, H, Greil, R ONKOLOGIE.
Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: updated results from a retrospective matched-pair analysis Gampenrieder, SP, Romeder, F, Muss, C, Pircher, M, Ressler, S, Rinnerthaler, G, Bartsch, R, Sattlberger, C, Mlineritsch, B, Greil, R Anticancer Res.
Two patients diagnosed with coexisting hematologic and oncologic BRAF VE mutated malignancies. Which entity is really carrying the BRAF VE mutation?
Schlick, K, Troch, M, Placher-Sorko, G, Faber, V, Neureiter, D, Greil, R, Hopfinger, G ONKOLOGIE. Aktuelle Diagnostik und Therapieoptionen bei aggressiven Lymphomen.
Hopfinger, G, Greil, R Bremen, London, Boston: UniMed Verlag, Mycophenolatmofetil und Azathioprin in der Schwangerschaft bei einer Patientin mit systemischem Lupus erythematodes.
Psenak, O, Studnicka-Benke, A, Greil, R Rheuma plus. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie.
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Dubsky P, Filipits M, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Kronenwett R, Brase JC, Gnant M Ann Oncol.
Epub Oct 3. Randomized phase II study of bortezomib, thalidomide and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.
Ludwig H, Viterbo L, Greil R, Masszi T, Spicka I, Shpilberg O, Hajek R, Dmoszynska A, Paiva B, Vidriales MB, Esteves G, Stoppa AM, Robinson D Jr, Ricci D, Cakana A, Enny C, Feng H, van de Velde H, Harousseau JL.
Continuation of bevacizumab after first progression in metastatic colorectal cancer ML : a randomised phase 3 trial. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial ABCSG 8.
Goetz MP, Suman VJ, Hoskin TL, Gnant M, Filipits M, Safgren SL, Kuffel M, Jakesz R, Rudas M, Greil R, Dietze O, Lang A, Offner F, Reynolds CA, Weinshilboum RM, Ames MM, Ingle JN.
Epub Dec 4. Topical evening primrose oil for reduction of bortezomib-induced skin reactions. Auberger J, Vogt S, Hopfinger G, Clausen J, Greil R.
Utility of PCR in diagnosis of invasive fungal infections: real-life data from a multicenter study. J Clin Microbiol. A case of long-term remission with ofatumumab maintenance therapy in multiply relapsed and rituximab-refractory chronic lymphocytic leukaemia with deletion 17p.
Namberger K, Weiss L, Krause B, Melchardt T, Greil R. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label non-inferiority phase 3 TURANDOT trial.
Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Messinger D, Zielinski C Lancet Oncol.
ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials.
Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Moore N, Prot S, Pallaud C, Semiglazov V.
Epub Apr 8. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group AMLSG.
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.
Epub Jun 3. Circulating tumor DNA to monitor metastatic breast cancer. Weiss L, Hufnagl C, Greil R. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML study KRAS subgroup findings.
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.
The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma. Expert Rev Anticancer Ther.
Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present and future. Gampenrieder SP, Rinnerthaler G, Greil R.
J Oncol. Greil R, Hiddemann W. Dtsch Med Wochenschr. Schlick K, Datz L, Hohla F, Greil R, Hopfinger G. Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Fisch K, Kronenwett R, Gnant M, Filipits M Br J Cancer.
Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report. Bezan A, Hohla F, Meissnitzer T, Greil R. Everolimus in postmenopausal, hormone receptor-positive advanced breast cancer: summary and results of an austrian expert panel discussion.
Gnant M, Greil R, Hubalek M, Steger G. Breast Care Basel. Influence of Body Mass Index on survival in indolent and Mantle-cell Lymphomas: Analysis of the StiL1 trial Weiss, L, Melchardt, T, Egle, A, Hopfinger, G, Greil, R, Barth, J, Rummel, M ONKOLOGIE.
Viral infections and their management in patients with chronic lymphocytic leukemia. Melchardt T, Weiss L, Greil R, Egle A.
Epub Jan 3. Taylor N, Melchardt T, Grundbichler M, Strasser M, Egle A, Greil R. Azacitidine in patients with WHO-defined AML - results of patients from the Austrian Azacitidine Registry of the AGMT-Study Group.
Pleyer L, Stauder R, Burgstaller S, Schreder M, Tinchon C, Pfeilstocker M, Steinkirchner S, Melchardt T, Mitrovic M, Girschikofsky M, Lang A, Krippl P, Sliwa T, Egle A, Linkesch W, Voskova D, Angermann H, Greil R.
Taylor N, Grabmeier-Pfistershammer K, Egle A, Greil R, Rieger A, Ledergerber B, Oberkofler H. Complications of 5-azacytidine: Three cases of severe ischemic colitis in elderly patients with myelodysplastic syndrome.
Melchardt T, Weiss L, Pleyer L, Steinkirchner S, Auberger J, Hopfinger G, Greil R, Egle A. Oncol Lett.
CDmediated activation of chronic lymphocytic leukemia cells promotes their CDdependent adhesion to hyaluronan and restricts CCLinduced motility.
Epub Nov 1. CXCR3 modulates CXCLmediated cellular responses in chronic lymphocytic leukemia Ganghammer, S, Hinterseer, E, Johrer, K, Greil, R, Hartmann, TN CYTOKINE.
Antiapoptotic effects of p21 regarding its subcellular localization in arsenic trioxide induced apoptosis in CLL Sifft, E, Hofbauer, JP, Asslaber, D, Hartmann, TN, Merkel, O, Greil, R ONKOLOGIE.
Mimicking the microenvironment in chronic lymphocytic leukaemia - where does the journey go? The transcription factor IRF-4 is related to prognosis in Chronic Lymphocytic Leukemia CLL and involved in proliferation and survival Asslaber, D, Hofbauer, JP, Zaborsky, N, Kocher, T, Hartmann, TN, Greil, R, Egle, A ONKOLOGIE.
Blockade of the Potassium Channel KCa3. A modified Phenol-chloroform extraction method for isolating circulating cell free DNA of tumor patients.
Journal of Nucleic Acids Investigation. DOI: Alexander Egle, Michael Steurer, Franz Josef Gassner, Roland Geisberger, Thomas Melchardt, Lisa Pleyer, Lukas Weiss, Michael A.
Fridrik, Josef Thaler, Alois Lang, Richard Greil, Blood ASH Annual Meeting Abstracts. Horejs-Hoeck J, Schwarz H, Lamprecht S, Maier E, Hainzl S, Schmittner M, Posselt G, Stoecklinger A, Hawranek T, Duschl A.
J Immunol. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med. Upgraded Cobas TaqMan version 2: hidden consequences at cohort level Taylor, N, Grabmeier-Pfistershammer, K, Oberkofler, H, Egle, A, Rieger, A, Ledergerber, B J INT AIDS SOC.
First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy dxxxAmore, F, Leppa, S, da Silva, MC, Relander, T, Brown, PD, Weidmann, E, Lauritzsen, GF, Pezzutto, A, Van Hoof, A, van Gelder, M, Doorduijn, JK, Wu, KL, Kluin-Nelemans, JC, Lugtenburg, PJ, Jankovska, M, Merup, M, Fagerli, UM, Walewski, J, Hagberg, H, Mariz, JM, Hansen, PB, Nosslinger, T, Janssens, A, Brandefors, L, Demuynck, H, Schaafsma, MR, Christiansen, I, Salek, D, Jyrkkio, S, Prochazka, V, Zijlstra, J, Bohmer, L, Greil, R, Stevens, W, Fijnheer, R, Kooy, MV, Grube, M, Hopfinger, G, Van den Neste, E, Jantunen, E, Trumper, L, Wulf, G, Altmann, B, Ziepert, M, Loeffler, M, Toldbod, H BLOOD.
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: results of a randomised phase III intergroup study initiated by the AIO and AGMT ML Greil, R, Arnold, D, Hegewisch-Becker, S, Freier, W, Steffens, CC, Bertram, M, Schlichting, C, Andel, J, Taylor, M, Makrutzki, M, Kubicka, S ONKOLOGIE.
Influence of the American ODAC statement upon Austrian prescription practice of bevacizumab in metastatic breast cancer Preusser, M, Fulop, G, Berghoff, AS, Heinzl, H, Steger, GG, Greil, R, Zielinski, CC, Bartsch, R ONKOLOGIE.
Bevacizumab BEV plus chemotherapy CT continued beyond first progression in patients with metastatic colorectal cancer mCRC previously treated with BEV plus CT: Results of a randomized phase III intergroup study TML study.
Arnold, D, Andre, T, Bennouna, J, Sastre, J, Osterlund, PJ, Greil, R, Van Cutsem, E, Von Moos, R, Reyes-Rivera, I, Bendahmane, B, Kubicka, S J CLIN ONCOL.
A year-old woman with locally advanced rectal cancer and a resectable synchronous hepatic metastasis: a case report.
Treating T-cell lymphoma: is there a light at the end of the tunnel? Hopfinger, G, Merkel, O, Melchardt, T, Greil, R, Magazine of European Medical Oncology.
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions. Valent P, Gastl G, Geissler K, Greil R, Hantschel O, Lang A, Linkesch W, Lion T, Petzer AL, Pittermann E, Pleyer L, Thaler J, Wolf D.
Epub Sep 7. J Cancer Res Clin Oncol. Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target.
J Mol Med Berl. Prognostic value of number of removed lymph nodes, number of involved lymph nodes and lymph node ratio in breast cancer patients enrolled onto trials of the Austrian Breast and Colorectal Cancer Study Group ABCSG.
Tausch C, Taucher S, Dubsky P, Seifert M, Reitsamer R, Kwasny W, Jakesz R, Fitzal F, Filipcic L, Fridrik M, Greil R, Gnant M. Ann Surg Oncol.
Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial.
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.
Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, Makhson AN, Cortes J, Lortholary A, Bischoff J, Chan A, Delaloge S, Huang X, Kern KA, Giorgetti C.
Epub Mar 3. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting CINV : the Pan European Emesis Registry PEER.
Epub Mar 6. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma HD15 trial : a randomised, open-label phase 3 non-inferiority trial.
Epub Apr 4. LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled multicenter multinational double-blinded phase II trial.
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.
Continuous lenalidomide treatment for newly diagnosed multiple myeloma. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-J?
Safety results from a phase III study TURANDOT trial by CECOG of first-line bevacizumab in combination with capecitabine or paclitaxel for HERnegative locally recurrent or metastatic breast cancer.
Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer.
Psenak O, Studnicka-Benke A, Greil R. Z Rheumatol. Effect of KRAS codon13 mutations in patients with advanced colorectal cancer advanced CRC under oxaliplatin containing chemotherapy.
Results from a translational study of the AIO colorectal study group. Reinacher-Schick A, Schulmann K, Modest DP, Bruns N, Graeven U, Jaworska M, Greil R, Porschen R, Arnold D, Schmiegel W, Tannapfel A.
Novel treatment avenues for peripheral T-cell lymphomas. Hopfinger G, Griessl R, Sifft E, Taylor N, Kenner L, Greil R, Merkel O. Expert Opin Drug Discov.
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study.
What paths are open for tackling increasing azole resistance in Aspergillus in the clinic? Expert Rev Anti Infect Ther. Hopfinger G, Merkel O, Melchardt T, Greil R.
Memo - Magazine of European Medical Oncology. Feasibility of anthracycline based treatment in unselected elderly DLBCL patients Melchardt, T, Weiss, L, Hufnagl, C, Neureiter, D, Kemmerling, R, Hopfinger, G, Greil, R, Egle, A ONKOLOGIE.
Treatment of Aggressive B-Cell Lymphoma in the Elderly: The Influence of SNPs Affecting Pharmacodynamics Is Different Compared to Younger Patient Thomas Melchardt, Lukas Weiss, Clemens Hufnagl, Daniel Neureiter, Ralf Kemmerling, Patrick Morre, Ann Boekstegers, Georg Hopfinger, Richard Greil, Alexander Egle, Blood ASH Annual Meeting Abstracts Merkel O, Wacht N, Sifft E, Melchardt T, Hamacher F, Kocher T, Denk U, Hofbauer JP, Egle A, Scheideler M, Schlederer M, Steurer M, Kenner L, Greil R.
Epub Jun 1. Chemokine-dependent B cell-T cell interactions in chronic lymphocytic leukemia and multiple myeloma - targets for therapeutic intervention?
Tarraf Daniel Lederman Danielle De Vooght Daniel Lednicer Danielle Doby Danielle Donaldson Danielle Dumontet Daniel Lee Daniel Lee Kleinman Danielle Elliott Range Danielle Fosler-Lussier Danielle Graver Danielle Harel Danielle Hipkins Daniel Leitold Danielle Jamie Danielle J.
Donnelly Danielle Kennedy Danielle King Danielle Knafo Danielle Kosecki Danielle Krysa Danielle Lazarin Danielle L'Heureux Danielle Libine Daniel Lelis Baggio Danielle Long Danielle Mackinnon Danielle Matthews Danielle Newnham Daniel Lenz Danielle Ofri Danielle Omar Danielle Pearl Danielle Petherbridge Danielle Raine Daniel Lerch Danielle Resnick Danielle S.
Allen Danielle Sanchez Danielle Sarver Coombs Danielle Shapiro Danielle Shawn Kurin Danielle Shroyer Danielle Steel Danielle Stein Fairhurst Danielle Strickland Danielle S.
Walsh Danielle Tate-Stratton Daniel Levin Becker Daniel Levitin Danielle Walker Daniel Lewis Daniel Lezano Daniel L. Fountain Daniel L.
Hamilos Daniel L. Hartl Daniel Liberzon Daniel Lieberman Daniel Lindeberg Daniel Ling Daniel Lipke Daniel Little Daniel Livescu Daniel L.
Merrifield Daniel L. Newman Daniel Lokshtanov Daniel L. Schacter Daniel L. Schafer Daniel L. Schwartz Daniel L. Smith-Christopher Daniel L.
Cobb Daniel M. Davis Daniel M Davis Daniel M. Doleys Daniel Memmert Daniel Mendelsohn Daniel Mersey Daniel Messelken Daniel Meyer-Dinkgräfe Daniel M.
Raff Daniel M. Greenberger Daniel M. Grimley Daniel M. Hausman Daniel Michelis Daniel Milford-Cottam Daniel Miller Daniel Milligan Daniel Minoli Daniel Mirman Daniel Mitel Daniel M.
Jones Daniel M. Kammen Daniel M Martinez Daniel Mohl Daniel Monterescu Daniel Monti Daniel Morat Daniel Morgan Daniel Morgensztern Daniel Morris Daniel Moulin Daniel M.
Russell Daniel M. Shea Daniel M. Shindler Daniel M. Allen Daniel Naumann Daniel N. Cassenti Daniel Ness Daniel Nettle Daniel Newman Daniel Nilsson Dehanas Daniel Ninan Daniel N.
Joudrey Daniel Oberhaus Daniel O'Brien Daniel O. Dahlstrom Daniel Oertli Daniel Ogden Daniel Olmen Daniel Olson Daniel O'Neill Daniel Ontaneda Daniel Oppenheimer Daniel O'Quinn Daniel O.
Sayers Daniel Paisner Daniel P. Aldrich Daniel Palmer Daniel Parker Daniel Patterson Daniel Pavlovits Daniel P.
Barr Daniel P. Bolger Daniel Pecaut Daniel Pedro Cardinali Daniel Perkins Daniel Perrin Daniel Peterson Daniel Philpott Daniel Pick Daniel Pine Daniel Pioske Daniel P.
Jenkins Daniel P. Keating Daniel Platt Daniel P. Loucks Daniel P. Murphy Daniel P. Newman Daniel Polani Daniel Polansky Daniel Pop Daniel P. Palomar Daniel Pratt Daniel P.
Raymer Daniel Priestley Daniel Pritchett Daniel P. Scheid Daniel Ps Goh Daniel P. Todes Daniel Pudelko Daniel Puncochar Daniel Purich Daniel Puschner Daniel P.
Watkins Daniel Quinn Mills Daniel Rabinovich Daniel Rachel Daniel Radu Daniel Rancour-Laferriere Daniel R. Schallmo Daniel R.
Brison Daniel R. Brooks Daniel Rees Dom Daniel Reid Daniel Reimold Daniel Reis Daniel Reisberg Daniel Rettig Daniel Reuschenbach Daniel R.
Fesenmaier Daniel R. Headrick Daniel R. Huebner Daniel Ribacoff Daniel Richard Daniel Richter Daniel Rieber Daniel Rietiker Daniel Riordan Daniel Ritchie Daniel Ritter Daniel Rixen Daniel R.
Marshak Daniel R. Mccarthy Daniel R. Melamed Daniel R. Müller Daniel Robinson Daniel Rode Daniel Roehr Daniel Roggen Daniel Rose Daniel Ross Daniel Roth Daniel Rothbart Daniel Rowles Daniel Roy Greenfeld Daniel R.
Perez Daniel R. Solin Daniel R. Spalding Daniel Ruben Prange Daniel Rubinfeld Daniel Rubio Daniel Rudofossi Daniel R. Valentine Daniel Sack Daniel Sanchez-Crespo Dalmau Daniel Sarewitz Daniel Sauble Daniel Saudek Daniel S.
Burt Daniel Schäfer Daniel Schagemann Daniel Schall Daniel Schallmo Daniel Schiffman Daniel Schlenk Daniel Schmicking Daniel Schoerling Daniel Scholten Daniel Scholz Daniel Schön Daniel Schreier Daniel Schubbe Daniel Schütz Daniel Schwartz Daniel Schwarz Daniel Schwenger Daniel Schwindt Daniel S.
Duick Daniel Sebastian Leidner Daniel Seddiqui Daniel S. Elson Daniel Senft Daniel S. Freed Daniel Shanks Daniel Shapiro Daniel Shepherd Msc Daniel S.
Horwitz Daniel Shumski Daniel Siemens Daniel Silber Daniel Sillivant Daniel Silver Daniel Silvert Daniel Simberloff Daniel Simon Daniel Simone Daniel Simson Daniel Sivan Daniel S.
Choy Daniel Slamanig Daniel S. Leon Daniel S. Medwed Daniel S. Mills Daniel Smith Daniel S. Mitrovic Daniel Snowman Daniel Solis Daniel Sousa Daniel S.
Putler Daniel S. Richter Daniel S. Riley Daniel S. Sem Daniel Star Daniel Starza Smith Daniel Stein Daniel Stelter Daniel Stephen Daniel Stern Daniel Stockemer Daniel Stoecklin Daniel Stone Daniel Stout Daniel Strange Daniel Strieff Daniels Tutorials Daniel Sui Daniel Susskind Daniel S.
Blumstein Daniel T. Gottuk Daniel Thalmann Daniel Thieme Daniel T. New Daniel Thomas Ginat Daniel Thurm Daniel Timmer Daniel T. Kline Daniel T. Koenig Daniel T.
Larose Daniel T. Shek Daniel T. Neely Daniel Todman Daniel T. O'Neill Daniel T. Pekarske Daniel Tranel Daniel Troy Case Daniel T.
Schwabe Daniel Tudor Daniel T. Willingham Daniel VöLker Daniel Valentin Daniel Vallero Daniel Van Soest Daniel Vaughan Daniel Vaughan-Whitehead Daniel Vaughn Daniel Ventre Daniel Verdier Daniel V.
Schroeder Daniel Wagenfuhrer Daniel Wagner Daniel Wallace Daniel Wallach Daniel Walter Daniel Waltner Daniel Walzer Daniel W.
Ambaye Daniel Watzenig Daniel W. Brown Daniel W Dieterle Daniel W. Drezner Daniel Weidner Daniel Weiss Daniel Weisser Daniel W. Gade Daniel W.
Halpin Daniel Wheeler Daniel Wiechmann Daniel Williams Daniel Wilson Daniel Wirls Daniel W. Koch Daniel Wolf Daniel Wollschlager Daniel Wollschläger Daniel Woolston Daniel W.
Patterson Daniel W. Smith Daniel W. Stroock Daniel W. Surry Daniel W. Korman Daniel Zwillinger Dani Gamerman Danijela Dolenec Danijela Kambaskovic-Sawers Danijel Dzino Dani Johnson Danila Aita Danilo Capecchi Danilo Demarchi Danilo Di Mauro Danilo Ercolini Danilo Garcia Danilo Jankovic Danilo Kis Danilo Raponi Danilo R.
Dani Shapiro Danita Catherine Burke Dani Tracz Dan Jenkins Dan John Dan Johnston Dan Jones Danjuma G. Dan Kusnetzky Dankwart Mattke Dan Landis Dan Leroy Dan Lewindon Dan Lewis Dan Ling Tang Dan L.
Longo Dan Lok Dan Longo Dan Louche Dan Luca Dan Luo Dan Lurie Dan Lusthaus Dan Lyons Dan Maharry Dan Maoz Dan Marcolina Dan Marcus Dan Marshall Dan Martin Dan Matthews Dan M.
Brown Dan Mccartney Dan Mcdonnell Dan Mercea Dan Meredith Dan Merkur Dan M. Fliss Dan Michaels Dan Michman Dan Mihai Stefanescu Dan Miller Dan Millman Dan Mont Dan Morhaim Dan M.
Roden Dan N. Dan Nagle Dannah Gresh Dannah K. Gresh Dan Nahorney Danna Korn Dan Nettleton Dan Nguyen Dannii Martin Dan Nixon Dan Norenberg Dan Norris Dan North Danny Aeberhard Danny Ajini Danny Banks Danny B.
Draper Danny Bernard Danny Bowien Danny Briere Danny Brooks Danny Chivers Danny Coeyman Danny Collins Danny Coremans Danny Coward Danny Dorling Danny Dover Danny Ertel Danny Geelen Danny Goodman Danny Greefhorst Danny Gregory Danny Hayes Danny Hermans Danny Iny Danny Jacobs Danny Kalman Danny Katch Danny Kavadlo Danny Kennedy Danny Kodicek Danny Kopec Danny L.
Barney Danny Lidgate Danny L. Jorgensen Danny L. Wiedbrauk Danny Macaskill Danny Mackinnon Danny Mangin Danny M. Goldberg Danny Nicol Danny O'Connor Danny Ong Danny Oppenheimer Danny Orbach Danny Pearson Danny Peary Danny Proulx Danny Rubin Danny Seo Danny Shipka Danny S Parker Danny S.
Parker Danny Staple Danny St Pierre Danny Vandenbroucke Danny Vendramini Danny Wallace Danny Weyns Danny Yann Dan O'Brien Dan O'Hair Dan Oja Dan Olsen Dan O'Neill Dan Pallotta Dan Pashman Dan Passarelli Dan P Bullard Dan Pedersen Dan Peer Dan Pilone Dan Pinchbeck Dan Plesch Dan P.
Felsenthal Dan Shadrake Dan Shafer Dan Shapiro Dan Sharp Dan Shideler Dan Shoemaker Dan Silverman Dan Simionescu Dan Simmons Dan Simon Dan Siroker Dan Sisson Dan S.
Kennedy Dan Slater Dan S Louche Dan Stefanica Dan Stein Dan Stone Dan Streetman Dan Sullivan Dan Tamir Dantar P. Oosterwal Dante Alighieri Dante M.
Grace Daphne M. West Daphne Oz Daphne Rose Kingma Daphne Selfe Daphne Simeon Daphne Simpkins Daphne Skillen Daphne Tuncer Daphne Vince-Prue D'Apice Dara Blumenthal Dara Brodsky Md Dara Conduit Dara D.
Brodsky Dara Downey Dara Duguay Daragh Downes Daragh Murray Dara Hoffman-Fox Dara L. Kraitchman Dara O' Briain Dara O'Rourke Darby English Darby Jones Darcia Narvaez Darcy Dougherty Maulsby Darcy Gaechter Darcy Hitchcock Darcy L.
Bigner Darell Tibbles Darell Wayne Fields Darel W. Hardy Dare Wells Dare Wilson Daria Bove Daria Dayter Daria Fissoun Dari Alexander Darian Leader Darice Bailer Darien Gee Darina Dicheva Darin Gibby Darin J.
Eich Darin Michaels Darin Olien Darin Workman Dario A. Bini Dario Antiseri Dario Azzellini Dario Bini Dario Bruneo Dario Calonaci Dario Cantu Dario Carlo Alpini Dario Castagno Dario Castiglione Dario Catalano Dario De Toffoli Dario Di Maio Dario Di Miao Dario Doller Dario D.
Pedersen Darlene E. Clover Darlene F. Russ-Eft Darlene Lancer Darlene Mannix Darlene Olivia Mcelroy Darlene Orlov Darlene Price Darlene Schacht Darlene Sredl Darlene Sweetland Darline Bergere Darl Kuhn Darlyne Gaynor Nemeth Darlyne G.
Roberts Darragh Greene Darra Goldstein Darran Jones Darrel A. Regier Darrel Hess Darrell A. Turkington Darrell Christian Darrell Clifton Darrell D.
Dorrell Darrell Duffie Darrell Ebbing Darrell Gurney Darrell Jobman Darrell L. Collins Darrell Long Darrell L. Ross Darrell Max Craig Darrell M.
Newton Darrell Morris Darrell M. West Darrell P. Arnold Darrell P. Hammer Darrell S. Pardi Darrell W. Pepper Darrell Young Darrel Moellendorf Darrel P.
Kaiser Darrel Ray Darrel R. Davis Darrel Rees Darren Ashby Darren Bagnall Darren Bradley Darren Cannell Darren Cook Darren Cummings Darren Dalcher Darren E.
Sherkat Darren E. Tromblay Darren Fa Darren Franck Darren George Darren Greenblatt Darren G. Rumbold Darren Hardy Darren Henley Darren Hill Darren Holloway Darren Humphrys Darren J.
Middleton Darren Jones Darren K. Bourke Darren K Patten Darren Langdridge Darren Laver Darren Levine Darren Lloyd Darren Mccauley Darren Nash Darren Nelson Darren Oldridge Darren Palmer Darren P.
Smith Darren Purchese Darren Quick Darren R. Flower Darren Richardson Darren Sheppard Darren Westwood Darren W Johnson Darril Gibson Darril Wilburn Darrin Lunde Darrin Nordahl Darrin Perez Darrin Wiggins Darrin Zeer Darron Cardosa Darrow Kirkpatrick Darrow Schecter Darryl Barton Darryl Charles Darryl Davis Darryl D.
Holm Darryl "Dmc" Mcdaniels Darryl Hocking Darryl K. Brown Darryl L. Felder Darryl Mcclelland Darryl Pinckney Darryl Plecas Darryl R.
Biggar Darryl Whetter Darryn J Reid Darsa P. Siantar Darsha Capaldi Darsham Singh Tatla Darshana Chandrakant Darshana Chandrakant Patel Darshana Jayemanne Darshana Thacker Dartnell Corp Da Ruan Darwen Darwin Growth Darwin Holmstrom Darwin L.
Conwell Darwin Ortiz Darwin Porter Darwin Porter Danforth Prince Darya Pino Rose Daryl Aaron Daryl Anthony Burrowes Daryl Easlea Daryl G.
Smith Daryl Hine Daryl Koehn Daryl Kulak Daryl Lee Daryl Mcphee Daryl R. Hillman Daryl S. Paulson Daryl Wise Daryl Wood Gerber Daryn Lehoux D.
Saia Dasarathi Das D. Asher Ghertner Dashiell Hammett Dashi Zhang Dashka Slater Dashner Dashu Qin Data D. Taylor Datenschutz Clou Datong Qin Dato' R.
Palan Dattaraj Rao Daud Alam D. Auers Daumantas Matulis Dava Sobel Dave Dave Allen Dave Anderson Dave Andrews Dave Asprey Dave Astle Dave Awl Dave Backwith Dave Bacon Dave Barnett Dave Barry Dave Barton Dave Beech Dave Berridge Dave Bidini Dave Birss Dave Broom Dave Brown Dave Calabrese Dave Canterbury Dave Carder Dave Celentano Dave Chaffey Dave Chambers Dave Clarke Dave Clayton Dave Collins Dave Conrey Dave Cormack Dave Craw Dave Crenshaw Dave Cutcher Dave D.
Chadee Dave Dewitt Dave Dictor Dave Doody Dave Eade Dave Eagle Dave Edlund Dave Eggers Dave Ellis Dave Engledow Dave Fleming Dave Ford Dave Gelly Dave Gentry Dave Gerr Dave Ghidiu Dave Gibbons Dave Gorman Dave Goulson Dave Gray Dave Grossman Dave Guymon Dave Hall Dave Hannigan Dave Hecker Dave Hendricks Dave Hendricksen Dave Hill Dave Hoekstra Dave Hollins Dave Holmes Dave Holston Dave Huitema Dave Hunter Dave Ingham Dave Ingram Dave Isay Dave Jackson Dave Johnson Dave Kansas Dave Kawula Dave Kelly Dave Kerpen Dave King Dave K.
Kythe Dave Kleiman Dave Lakhani Dave Lawrence Dave Levitan Dave Lewis Dave Lippert Dave Long Dave Lowry Dave Maccar Dave Maclean Dave Matthews Band Dave Mccomb Dave Mcguire Dave Mckenna Dave Mendonca Dave Minter Dave Myers Dave Nichols Dave Nicolette Dave O'Brien Dave O'Connor Dave Paradi Dave Parks Dave Peebles Dave Poon Dave Ramsey Dave Randall Dave Randolph Dave Rasdal Dave Reay Dave Revsine Dave Richards Daverick Leggett Dave Rigby Dave Robinson Dave Schmitz Dave Schwensen Dave Scotland Dave Shampine Dave Sherry Dave Shreiner Dave Smith Dave S.
Steinberg Dave Sterrett Dave Sworder Dave Taylor Dave Thau Dave Thomas Dave Thompson Dave Tomar Dave Trott Dave Ulrich Dave Van Ronk Dave Vizard Dave Walters Dave Warner Dave Wedge Dave Whitehead Dave Whitlock Dave Williams Davey Shafik Dave Zdanowicz Dave Zirin Dave Zwieback David David A.
Adler David Aaker David A. Ansell David Aaron Gaffen David A. Atwood David A. Bainbridge David A. Baker David A. Baldwin David A.
Baron David A. Baum David Abbott David A. Bell David A. Bello David A. Belsley David A Bender David A. Bender David A. Black David A. Miller David A.
Bolnick David A. Bradt David Abram David Abramson David Abulafia David A Carbonell David A. Cheresh David A. Chin David A.
Clark David A. Clarke David A. Cleveland David A. Coley David A. Cooper David Acord David A. Cox David A.
Cremers David Acres David A. Crighton David Adam David Adams David Adamy David Addyman David A. Decenzo David A. Deming David A.
Dieterle David A. Dowe David A. Dyker David A. Eberhard David A. Eberth David A Edwards David A. Ellis David A. Fahrenthold David A. Fennell David A.
Fiellin David A. Gordon David A. Graff David A. Green David A. Greenberg David Ahearn David A. Hensher David A. Hill David A. Holdstock David A.
Hollinger David A. Hughes David A. Jobes David A. Seargent David A. Karp David A Kay David A. Kay David A. Kilpatrick David A. King David A. Kopriva David A.
Krohn David A. Labonte David A. Lake David A. Lambert David Alan David Alan Black David Alan Grier David Alan Herzog David Alan Johnson David Alan Parnell David A.
Lavis David Alberts David Albertson David Alderson David A. Leeming David Alexander David Alexander Brannan David Alfandre David A. Liberles David Allan David Allen David Allen Wizardgold David Alonso-Gutierrez David Altchek David Althaus David A.
Lynch David Alzofon David A. Madsen David A. Makin David A. Mcentire David A. Mcgowan David Amerland David A. Messenger David A. Micha David A.
Michelson David A. Mindell David A Mitchell David Amo David A. Montague David A. Morton David A. Moss David Anderson David Andress David Andrews David Andrich David Annal David A.
Norris David Anthony David Anthony Fanella David A Owens David A. Papa David A. Parker David A. Pelta David A. Peterson David A.
Phoenix David A. Pietz David Appelbaum David Applebaum David Applefield David A. Puleo David A. Purser David Arase David Archuleta David Arditi David Aretha David Armentrout David Armine Howarth David Armitage David Armstrong David Arnold David A.
Rosenbaum David A. Rothery David A. Sather Jr. David A. Savitz David Asch David Ascher David A. Schwartz David Asen David A. Shafer David Asher David Ashford David Ashforth David A.
Smith David A.